Method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate

a technology of nicotinamide and dinucleotide, which is applied in the direction of biocide, drug composition, cardiovascular disorder, etc., can solve the problems of difficult formulation, narrow safety zone, and ascorbic acid giving a taste to tablets

Inactive Publication Date: 2005-06-02
KYOWA HAKKO KOGYO CO LTD
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0036] When the preparation of the present invention is produced as an enteric coated capsule, it is possible to produce the preparation as a soft capsule or a hard capsule by conventional methods.
[0048] In the preparation of the present invention, the NAD(P)H contained in the preparation is kept stable because of astaxanthin which is included, and thus the preparation can effectively act as an auxiliary nutritional agent in vivo.

Problems solved by technology

However, since NAD(P)H is unstable at ambient temperature, it have been prevalent that means to formulate the NAD(P)H are taken.
However, as to polyvinylpyrrolidone there is a problem in that a safety zone is narrow.
Tocopherol is oil and thus is difficult to formulate.
Also, there is a problem in that ascorbic acid give a taste to tablets.
However, the action of astaxanthin to stabilize NAD(P)H has not been known.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0050] Fifty grams of NADH (supplied by Kyowa Hakko Kogyo Co. Ltd.), 500 g of astaxanthin (containing 1% by weight of ester derived from blue-green algae; supplied by Fuji Chemical Co. Ltd.) and 450 g of mannitol (supplied by Nikken Chemical and Synthetic Industry Co. Ltd.) were mixed and stirred. The mixture was placed in a capsule filling machine, and filled into, 5000 tablets of hard capsules No. 2 made of gelatin. The resultant hard capsule was coated with zein solution to prepare an enteric coated capsule (Capsule 1) containing 10 mg of NADH and 1 mg of astaxanthin.

example 2

[0051] Two hundred grams of NADH (supplied by Kyowa Hakko Kogyo Co. Ltd.), 200 g of astaxanthin (containing 1% by weight of ester derived from blue-green algae; supplied by Fuji Chemical Co. Ltd.), 3560 g of mannitol (supplied by Nikken Chemical and Synthetic Industry Co. Ltd.) and 40 g of silica dioxide were mixed and stirred. The mixture was placed in a capsule filling machine, and filled into 20000 tablets of hard capsules No. 2 made of gelatin. The resultant hard capsule was coated with zein solution to prepare an enteric coated capsule containing 10 mg of NADH and 0.1 mg of astaxanthin.

example 3

[0053] Capsules 1 prepared in Examples 1 and Capsule a prepared in Comparative example 1 were separately placed into glass bottles. After sealing and shielding the light, the bottles were stored at 60° C. for 33 hours. The stored capsules were opened at the start of the storage, at 14 and 33 hours after the start of the storage, and each of the samples was dissolved in 10 mmol / l of Na2CO3 buffer (pH 10).

[0054] Each solution was filtered trough a membrane filter (0.45 μm), and subsequently, the absorbance was measured at 340 nm using a model U-3210 self-recording spectrometer (supplied by Hitachi Ltd.). Based on the absorbance at the start of the storage defined as 100%, the values of the absorbance at 14 and 33 hours after the start of the storage were calculated, which were rendered a residual ratio of NADH.

[0055] The results are shown in Table 1.

TABLE 1Residual rate of NADH (%)Capsule No.in 14 hoursin 33 hours178.483.2a47.513.3

[0056] According to Table 1, in Capsule 1 containi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

It is an object of the present invention to provide a method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate [hereinafter abbreviated as NAD(P)H] and a preparation containing NAD(P)H stabilized by the method. As the method of stabilizing NAD(P)H, a method of adding astaxanthin to NAD(P)H is provided.

Description

TECHNICAL FIELD [0001] The present invention relates to a method of stabilizing reduced nicotinamide adenine dinucleotide (hereinafter abbreviated as NADH) or reduced nicotinamide adenine dinucleotide phosphate (hereinafter abbreviated as NADPH) and a preparation containing NADH or NADPH [hereinafter abbreviated as NAD(P)H]. BACKGROUND ART [0002] NADH is known to be effective for hypertension (U.S. Pat. No. 5,668,114), Parkinson's disease (U.S. Pat. No. 5,019,561) and Alzheimer disease (U.S. Pat. No. 5,444,053). Also NADPH is known to be effective for hypertension (U.S. Pat. No. 5,668,114) and Parkinson's disease (U.S. Pat. No. 5,019,561). [0003] NAD(P)H has been widely used for preventive supplements (auxiliary nutritional agents) for these adult diseases. [0004] However, since NAD(P)H is unstable at ambient temperature, it have been prevalent that means to formulate the NAD(P)H are taken. [0005] Addition of a stabilizer such as polyvinylpyrrolidone, sodium hydrogen carbonate, toco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7084
CPCA61K31/7084A61K2300/00A61P25/16A61P25/28A61P9/12
Inventor KAWABE, HIDEOMURATA, HIDEKINAGANO, HIROSHI
Owner KYOWA HAKKO KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap